SBIR/STTR Research Award
SYNTHESIS OF MONOMERIC CARCINOGEN-DNA ADDUCTS
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1989Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Karkinos Biochem Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
RESEARCH ON MECHANISMS IN CHEMICAL CARCINOGENESIS OFTEN REQUIRES AUTHENTIC MONOMERIC CARCINOGEN-DNA ADDUCTS. FEW ADDUCTS ARE COMMERCIALLY AVAILABLE, AND INDIVIDUALS OFTEN OBTAIN SUBMILLIGRAM LEVELS OF ADDUCTS FROM CARCINOGEN-TREATED DNA; THIS MAY BE INSUFFICIENT FOR THEIR NEEDS. THE OBJECTIVE OF THIS PROJECT IS TO DETERMINE THE FEASIBILITY OF DEVELOPING GENERIC APPROACHES TO GRAM-SCALE SYNTHESIS OF CARCINOGEN-DNA ADDUCTS THAT MAY BE USED IN MODERN MOLECULAR TOXICOLOGY STUDIES AS POSTLABELING OR CHROMATOGRAPHY STANDARDS, IN DEVELOPING IMMUNOASSAYS, OR FOR INCORPORATION INTO OLIGONUCLEOTIDES. THIS PROJECT WILL SPECIFICALLY ADDRESS PREPARATION OF 3'-MONOPHOSPHATES OF MAJOR ADDUCTS OF DG AND DA WITH 7-BROMOMETHYL-12-METHYLBENZANTHRACENE (BMBA) OR BENZO(A)PYRENE DIOLEPOXIDE I (BPDE), AS STANDARDS FOR THE (32)P-POSTLABELING ASSAY. SILYLATION VERSUS ACYLATION WILL BE EVALUATED FOR TRANSIENT PROTECTION OF BPDE AND DEOXYRIBOSE HYDROXYLS; THEIR STABILITY DURING PHOSPHORYLATION AND EASE OF SELECTIVE REMOVAL WILL BE CHECKED. O-SILYLATED OR -ACYLATED AMINES (FROM AMMONIATION OF BPDE OR BMBA) WILL BE CONDENSED WITH THE APPROPRIATE PROTECTED HALOPURINE NUCLEOSIDE TO YIELD FULLY BLOCKED N(2)-DG OR N(6)-DA DERIVATIVES. PHOSPHORYLATION WILL FOLLOW SELECTIVE REMOVAL OF THE 3'-PROTECTING GROUP.
Technology keywords
Not reported